Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) – Equities researchers at Roth Capital raised their FY2016 earnings per share estimates for Catalyst Pharmaceutical Partners in a note issued to investors on Thursday. Roth Capital analyst S. Henry now anticipates that the brokerage will earn ($0.24) per share for the year, up from their previous forecast of ($0.25). Roth Capital currently has a “Buy” rating and a $2.50 target price on the stock. Roth Capital also issued estimates for Catalyst Pharmaceutical Partners’ Q4 2016 earnings at ($0.07) EPS and FY2018 earnings at ($0.15) EPS.

Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01.

Earnings History and Estimates for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)

Separately, Piper Jaffray Cos. upgraded shares of Catalyst Pharmaceutical Partners from a “neutral” rating to an “overweight” rating and set a $4.00 target price on the stock in a report on Wednesday, October 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $3.38.

Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.14 on Monday. The firm’s market capitalization is $94.47 million. The company has a 50-day moving average of $1.16 and a 200 day moving average of $0.88. Catalyst Pharmaceutical Partners has a 52 week low of $0.51 and a 52 week high of $3.00.

Several institutional investors have recently made changes to their positions in CPRX. Oxford Asset Management raised its position in shares of Catalyst Pharmaceutical Partners by 3.5% in the second quarter. Oxford Asset Management now owns 180,721 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 6,140 shares in the last quarter. Northern Trust Corp increased its stake in Catalyst Pharmaceutical Partners by 41.2% in the third quarter. Northern Trust Corp now owns 127,584 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 37,217 shares during the last quarter. Berson & Corrado Investment Advisors LLC increased its stake in Catalyst Pharmaceutical Partners by 76.1% in the third quarter. Berson & Corrado Investment Advisors LLC now owns 181,900 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 78,600 shares during the last quarter. Point72 Asset Management L.P. increased its stake in Catalyst Pharmaceutical Partners by 4.6% in the second quarter. Point72 Asset Management L.P. now owns 2,366,964 shares of the biopharmaceutical company’s stock valued at $1,681,000 after buying an additional 103,388 shares during the last quarter. Finally, Royal Bank of Canada acquired a new stake in Catalyst Pharmaceutical Partners during the second quarter valued at approximately $117,000. Hedge funds and other institutional investors own 30.31% of the company’s stock.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

5 Day Chart for NASDAQ:CPRX

Receive News & Stock Ratings for Catalyst Pharmaceutical Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceutical Partners Inc. and related stocks with our FREE daily email newsletter.